U.S. Markets close in 2 hrs 9 mins

AdaptImmune partners to advance promising cancer immunotherapies

John George
AdaptImmune partners to advance promising cancer immunotherapies

Alpine gets $2 million from Adaptimmune now, and up to $290 million if the partnership is successful in producing next-generation cancer immunotherapies.